Company Overview and News

 
Blue Sky Uranium Step-Out Drilling Program Confirms Expansion at Ivana Deposit, Amarillo Grande Project, Argentina

2018-10-09 globenewswire
VANCOUVER, British Columbia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V: BSK, FSE: MAL2; OTC: BKUCF), "Blue Sky" or the "Company") is pleased to announce that results from the recently completed reverse circulation (RC) drilling program have confirmed the southern expansion of the Ivana Uranium-Vanadium deposit on its wholly-owned Amarillo Grande Uranium-Vanadium project in Rio Negro, Argentina.
BSK BKUCF

 
Blue Sky Uranium VP Exploration Receives “Explorer of the Year” Award

2018-09-13 globenewswire
VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V: BSK, FSE: MAL2; OTC: BKUCF), "Blue Sky" or the "Company") is pleased to announce that Guillermo Pensado, Vice President of Exploration, received the “Explorer of the Year” Nivaldo Rojas Award at the 2018 Argentina Mining conference last week. Nominees for the award are put forth and voted on by members of the exploration and mining community attending the annual conference, which is the premium international event of the Argentinean mining sector.
BSK BKUCF

 
Blue Sky Uranium Completes Targeted RC Drilling Program at Ivana Deposit, Amarillo Grande Project, Argentina

2018-09-11 globenewswire
VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V: BSK, FSE: MAL2; OTC: BKUCF), "Blue Sky" or the "Company") is pleased to announce that it has carried out a 61-hole 1,029 metre reverse circulation (RC) drilling program at the Ivana Uranium-Vanadium deposit on its wholly-owned Amarillo Grande Uranium-Vanadium project in Rio Negro, Argentina. The drilling program covered targeted areas, adjacent to the current mineral resource, which were identified by auger drilling and radiometric probe to have strong potential for delineation of deposit extensions.
BSK BKUCF

 
Blue Sky Uranium Applies to Extend Warrants

2018-08-15 globenewswire
VANCOUVER, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V: BSK, FSE: MAL2; OTC: BKUCF), ("Blue Sky" or the "Company") announces that the Company has made an application to the TSX Venture Exchange to extend the term of the outstanding warrants as follows:
BSK BKUCF

 
Blue Sky Uranium Updates Activities at Amarillo Grande Project, Argentina

2018-08-01 globenewswire
VANCOUVER, British Columbia, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF) ("Blue Sky" or the "Company") is pleased to provide an update on activities at its wholly-owned Amarillo Grande Uranium-Vanadium project in Rio Negro, Argentina. The Company is currently engaged in completing metallurgical testing to support the Preliminary Economic Assessment (PEA) study it plans to complete by year-end, as well as conducting exploration work to identify and delineate additional resources.
BSK BKUCF

 
Blue Sky Uranium Oversubscribed - Company Closes Final Tranche of Non-Brokered Private Placement

2018-06-14 globenewswire
VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSXV:BSK) (FSE:MAL2) (OTC:BKUCF) ("Blue Sky" or the "Company") is pleased to announce it has closed the final tranche of the non-brokered private placement financing announced on June 1, 2018 and increased on June 4, 2018 consisting of 1,428,572 units in this tranche for a total of 24,906,588 units at a price of $0.
BSK BKUCF

 
Blue Sky Uranium Oversubscribed - Company Closes Non-Brokered Private Placement

2018-06-12 globenewswire
VANCOUVER, British Columbia, June 12, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is pleased to announce it has closed the first tranche of the non-brokered private placement financing announced on June 1, 2018 and increased on June 4, 2018 consisting of 23,479,016 units at a price of $0.14 per unit for gross proceeds of $3,287,062.
BSK BKUCF

 
Blue Sky Uranium Increases Non-Brokered Private Placement

2018-06-04 globenewswire
VANCOUVER, British Columbia, June 04, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") announces that due to high investor demand, the Company has increased the private placement amount announced on June 1, 2018 from $2,660,000 to $3,080,000 consisting of 22 million units (the “Units”) at $0.14 per Unit.
BSK BKUCF

 
Blue Sky Uranium Announces

2018-06-04 globenewswire
VANCOUVER, British Columbia, June 04, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is a member of the Grosso Group and is the 100% owner of approximately 459,000 hectares (1,134,000 acres) of uranium and vanadium concessions in Argentina in the southern provinces of Chubut and Río Negro, Argentina.
BSK BKUCF

 
Blue Sky Uranium Announces Non-Brokered Private Placement

2018-06-01 globenewswire
VANCOUVER, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is pleased to announce a non-brokered private placement financing of up 19,000,000 units at a price of $0.14 per unit for gross proceeds of $2,660,000. Current shareholders have expressed interest to acquire a significant majority of this financing.
BSK BKUCF

 
Blue Sky Uranium Reports Positive Concentration Tests for Uranium and Vanadium at Amarillo Grande Project, Argentina

2018-05-23 globenewswire
VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is pleased to report that the initial process testing on oxide material from the Company’s Ivana uranium-vanadium deposit demonstrated that simple wet scrubbing followed by wet screening results in the upgrading of metal concentration by approximately 300% for Uranium and 250% for Vanadium.
BSK BKUCF

 
Blue Sky Uranium (BKUCF) Presents At International Mining Investment Conference - Slideshow

2018-05-16 seekingalpha
The following slide deck was published by Blue Sky Uranium Corp. in conjunction with this event.
BSK BKUCF

13
Expert Uranium Metallurgist Joins Blue Sky Uranium Team as it Advances Amarillo Grande Uranium-Vanadium Project, Argentina

2018-05-09 globenewswire
VANCOUVER, British Columbia, May 09, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF) ("Blue Sky" or the "Company") is pleased to report it has engaged Chuck Edwards P.Eng. as a technical advisor to assist the Company in planning and managing beneficiation (upgrading) and metallurgical studies and process design for the Ivana Uranium-Vanadium deposit and the Amarillo Grande project.
AMFW BSK BKUCF AMCBF AMFW CCJ

 
Blue Sky Uranium Files NI 43-101 Technical Report for the First Mineral Resource Estimate at Amarillo Grande Uranium-Vanadium Project, Argentina

2018-04-18 globenewswire
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is pleased to announce that the Company has filed the NI 43-101 Technical Report (the “Report”) supporting disclosure of the initial independent mineral resource estimate for the Ivana Deposit at the Company’s 100% owned Amarillo Grande Uranium-Vanadium Project in Rio Negro Province, Argentina, as reported on March 5th, 2018.
BSK BKUCF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...